Picture of Zevra Therapeutics logo

ZVRA Zevra Therapeutics Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapMomentum Trap

Annual cashflow statement for Zevra Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-12.8-8.55-41.5-46-106
Depreciation
Non-Cash Items10.219.126.18.8636.5
Unusual Items
Purchased R&D
Other Non-Cash Items
Changes in Working Capital0.374-0.357-4.252.65-7.07
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities-1.9410.4-18.7-33.5-69.7
Capital Expenditures-0.033-0.102-0.093-0.296-6
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items-15.4-36.6-17.1-16.2
Acquisition of Business
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities-0.033-15.5-36.7-17.4-22.2
Financing Cash Flow Items-0.11873.9-0.0330.692-1.44
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities2.741138.3528.582.1
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash0.767108-46.9-22.4-9.26